{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"36","value":"27"},{"groupId":"OG001","spread":"13","value":"9"}]}],"title":"E2 at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5","value":"5"},{"groupId":"OG001","spread":"20","value":"10"}]}],"title":"E2 at 4 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12","value":"9"},{"groupId":"OG001","spread":"7","value":"8"}]}],"title":"E2 at 12 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"serial measurements of serum estradiol (E2) by liquid chromatography tandem mass spectrometry (Quest Diagnostics)","dispersionType":"Standard Deviation","groups":[{"description":"Estring 2mg ring inserted vaginally once every 12 weeks","id":"OG000","title":"Estring"},{"description":"Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment","id":"OG001","title":"Testosterone Cream"}],"paramType":"MEAN","populationDescription":"Per protocol, participants who completed 12 weeks of assigned treatment","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Serum Estradiol (E2)","type":"SECONDARY","unitOfMeasure":"pg/ml"}